Background: A complex ventral hernia requiring abdominal wall reconstruction presents a challenging scenario to the surgeon. The use of biologic mesh in addition to performing a components separation (CS) is controversial. Our goal was to perform the first cost-utility analysis on the use of biologic mesh in addition to performing CS when performing complex ventral hernia repair. Methods: A comprehensive literature review was conducted to identify published complication and recurrence rates for ventral hernia repairs requiring CS with or without biologic mesh. The probabilities of the most common complications were combined with Medicare Current Procedural Terminology reimbursement codes, diagnosis related group reimbursement codes, and expert utility estimates to fit into a decision model to evaluate the cost utility of CS with and without biologic mesh in reconstructing ventral hernias.
C omplex abdominal wall reconstruction of large ventral hernias not amenable to primary suture closure is a challenging problem for the surgeon. The components separation (CS) technique described in 1990 by Ramirez et al 1 provided a valuable tool in the surgeon's armamentarium when dealing with large ventral hernia defects, allowing for a decreased tension closure of the abdominal wall that would otherwise either require lengthening the abdominal incision or would not allow for primary closure. Recently, the placement of biologic mesh as an underlay in addition to performing a CS has been described with results suggesting decreased hernia recurrence. 2 Biologic mesh, as opposed to synthetic, permanent mesh, can be used in a contaminated surgical field. 3 Cost-utility analysis is a form of economic analysis that incorporates the patient's preferences in addition to acknowledging the costs for potential complications. 4Y8 Given the discrepancy between clinical benefit derived from decreased hernia recurrence yet increased cost, the goal of this study was to perform a costutility analysis of using biologic mesh in addition to CS when performing ventral hernia reconstruction in contaminated surgical fields. To our knowledge, there has been no such previous cost economic study analyzing this question.
METHODS
As with most novel interventions, use of biologic mesh is costlier yet associated with increased clinical efficacy and is the basis for cost-utility analysis. Cost-utility analysis is comprised of costs, probabilities, and utilities of various health outcomes that are used to evaluate competing interventions.
Perspective
The perspectives of both a third-party payer (Medicare) and the hospital/physician were adopted for the decision analysis.
Health States
The relevant surgical literature was explored to properly identify the most clinically relevant and common outcomes associated with complex ventral hernia repair using CS. These outcomes were separated by time course with early complications comprising wound infection, wound dehiscence, seroma, and hematoma; and late complications including enterocutaneous fistula, small bowel obstruction, abdominal bulging/laxity, and hernia recurrence. Infections (eg, simple cellulitis) requiring oral antibiotics were excluded as these could be from a reaction to the biologic mesh itself. 9 Each distinct outcome was associated with probabilities, costs, and utilities for use in the decision model.
Costs
The costs for complex ventral hernia repair were based on Medicare national average facility reimbursement Current Procedural Terminology (CPT) codes for inpatients corresponding to ''repair initial/recurrent incisional or ventral hernia reducible'' (49560/ 49565), ''muscle, myocutaneous, or fasciocutaneous trunk'' (15734), ''closure of intestinal cutaneous fistula'' (44640), ''enterolysis'' (44005), ''secondary closure of dehiscence'' (13160), ''incision and drainage of hematoma or seroma'' (10140), and ''incision and drainage for complex postoperative wound infection'' (10180). The diagnosis related group (DRG) code corresponding to hernia repair without complication (355) was used for a successful outcome, hernia repair with complication (354) was used for outcomes with early complications (within 30 days of admission), and separate DRG codes (909 and 336) were used for enterocutaneous fistula and small bowel obstruction (require readmission after 30 days). For the other long-term complications (hernia recurrence and abdominal bulging/laxity) requiring subsequent hernia repair, the DRG code for hernia repair without complication (355) was repeated. All payment data were based from 2012 Medicare CPT and DRG reimbursement national averages. 10, 11 Costs for each health state involved the cost of a successful surgery and its complications. The increased cost associated with biologic mesh was derived from the LifeCell company 2012 pricing catalogue, which listed the Medicare CPT code corresponding to professional reimbursement for ''implantation of mesh for ventral hernia repair'' (49568). The medical institution receives no other financial reimbursements for using biologic mesh. The reimbursement was the same ($268.22) regardless of the size of biologic mesh used and was significantly lower than the actual cost of the material. This was added to the hospital cost of a complex ventral hernia repair for all health states involving biologic mesh.
Retail costs were based on the LifeCell company 2012 pricing catalogue for a 10 Â 25-cm Strattice mesh ($32.38/cm 2 ) (LifeCell, Branchburg, NJ). This cost was added to the hospital cost of complex ventral hernia repair for all health states involving biologic mesh as part of the cost sensitivity analysis. Strattice was selected because it was one of the most commonly used biologics in the studies analyzed and is one of the most commonly used biologics in practice today.
Recovery
Assumptions were made regarding the appropriate follow-up for health states based on the current practice of plastic surgeons at our institution. In terms of early complications, costs for wound infection assumed that patients required hospital admission and the administration of IV antibiotics and patients would recover within 30 days. Patients experiencing wound dehiscence were assumed to undergo surgical closure and recover within 30 days. Large hematomas and seromas are drained under anesthesia by the surgeon in the major operating room within 30 days.
Costs for long-term complications assumed that the patient did not experience an early complication and required readmission after 30 days. Patients were assumed to recover from long-term (late) complications within 3 months. Patients experiencing hernia recurrence could either undergo surgical revision or elect to live with a persistent hernia. Those undergoing surgical revision would either have a successful result or another hernia recurrence, which was assumed to be successfully revised with subsequent surgery. Modeling a maximum of 2 hernia recurrences after initial presentation with a ventral hernia was felt to cover all published patient outcomes and encompass the population of patients experiencing complex ventral hernias.
Probabilities
The probabilities associated with clinically relevant health states were obtained for complex ventral hernia repair using CS with or without biologic mesh. Probabilities of health states when using CS alone were derived from a thorough review of the literature using the Cochrane and MEDLINE electronic databases with key words ''components separation,'' ''ventral hernia,'' and limiting findings to human subjects undergoing ventral hernia repair with CS and English-language articles. Additionally, articles resulting from the search for biologic mesh were examined with preference given to studies that examined matched cohorts of patients undergoing CS with and without biologic mesh. Patients with Ventral Hernia Workgroup (VHWG) grade 2 to 4 complex ventral hernias were included. 3 This search revealed 14 published studies which included 527 ventral hernias in patients who underwent CS without biologic mesh. Data were extracted, pooled, and weighted by study size as previously described ( Table 1) .
The probabilities for biologic mesh were derived from a literature review using the Cochrane and MEDLINE electronic databases with key words ''components separation,'' ''mesh,'' ''hernia repair'' and limiting findings to human subjects, ventral hernia repairs using CS with biologic mesh, and English-language articles. Patients with VHWG grades 2 to 4 were included. 3 This search revealed 10 published studies that included 360 ventral hernias in patients who underwent CS with biologic mesh. Data were extracted from the relevant publications and pooled together and weighted by the size of each study ( Table 2) .
Utilities
The utilities used in this study were obtained through a survey of 11 surgeons at our institution, including both plastic and reconstructive surgeons and general surgeons, who had the most Vries et al 14  19  3  1  4  1  0  0  0  10  2Y3  Clarke 15  63  2  0  0  0  0  0  0  12  2  de Vries et al 16  43  6  1  2  5  0  0  0  12  3  Ramirez 1  11  0  0  0  0  0  0  0  0  3Y4  Girotto 17  33  8  0  1  2  1  1  0  2  3  Shestak 18  22  2  2 1 0 0 0 0 1 3Y4 Cohen 19 24 22 41 23 11 experience with abdominal wall reconstruction and represented diverse training backgrounds. The practice of surveying physicians to acquire utility scores has empirical precedent in the literature. 6, 7 The survey involved evaluating outcomes associated with complex ventral hernia repair with or without biologic mesh, and all surgeons were given visual analog models. These experts were posed with identical scenarios involving each health state and were asked to rank their preferences such that the quality of life for each health state was marked on a ''feeling thermometer,'' a vertical ladder of 10 cm in height ascending from a score of 0 (death) to 1 (perfect health). The overall utility of each health state was the average of the expert opinion.
The utilities were converted to quality-adjusted life-years (QALYs) by multiplying the utility of a specific health state by the duration of that health state and adding that to the remaining life years multiplied by the utility of a successful operation. The remaining life years was derived from the assumption that the average patient undergoing ventral hernia repair is 50 years old and has a life expectancy of 78.3 years. 33 An example for the ''seroma'' health state involves the assumption that a seroma would be expected to improve in 30 days, the average utility for experiencing a ''seroma'' is 0.71, and the utility of a successful surgery without complication is 0.81. The previously mentioned steps were performed for all health states (Table 3) .
Duration of Health State

Analysis
A decision model was created for these data (Fig. 1 ) with the 2 main branches being CS with biologic mesh and CS alone. The costs and QALYs for each health state were incorporated into this model along with the probabilities of all the health states relevant to complex ventral hernia repair. Expected values for costs and 13 18 25 26 27 14 1 0 2 0 3 0 0 0 2Y3 Kolker 28 16 29 22 outcomes were derived by multiplying the probability of a health state by its cost and QALY. These expected values were summed for both arms using the roll-back method to derive the overall expected cost and utility (QALY) for a complex ventral hernia repair with and without biologic mesh (Table 3 ). The incremental costutility ratio (ICUR) was then calculated using the following formula:
ICUR ¼ ðExpected cost of CS with biologic meshj Expected cost of CS without biologic meshÞ ðExpected QALY of CS with biologic meshj Expected QALY of CS without biologic meshÞ A novel intervention is ''cost-effective'' if the ICUR is greater than 0 and less than the ''willingness to pay (WTP)'' for an added year of perfect health, for which we used the accepted and previously published threshold of $50,000 as described in the following:
Cost Effective: ICUR 9 0 and G WTP; WTP ¼ /50; 000=QALY One-way sensitivity analysis was performed to determine if the baseline decision analysis was robust by varying the rate of early and late complications and hernia recurrence without biologic mesh from 0 to 1 (at 0.01 intervals) while keeping the complication rate when using biologic mesh fixed and observing how this affected the ICUR. Further sensitivity analyses were done to determine how the price of mesh and the variation in utility estimates altered the cost-effectiveness of using biologic mesh.
The analysis was performed using TreeAge Pro 2012 (Williamstown, Mass).
RESULTS
In ventral hernia repair using CS, using biologic mesh resulted in a lower rate of hernia recurrence, wound infection, and hematoma but resulted in higher rates of wound dehiscence, seroma, enterocutaneous fistula, small bowel obstruction, and abdominal bulging/laxity (Fig. 2) .
When using Medicare reimbursement rates, the cost-utility analysis revealed an expected cost increase of $775.65 when using biologic mesh with CS to repair complex ventral hernias. There was a 0.0517 gain in QALYs with biologic mesh yielding a costeffective incremental ICUR of $15,002.90/QALY. Using biologic mesh with CS was cost-effective when the hernia recurrence using CS alone was 16% or higher (Table 4) .
When using the retail price for Strattice ($8095) for a size (10 Â 25 cm) appropriate to cover the average defect from our pooled studies (230 cm 2 ), the ICUR was $187,069.44/QALY (costineffective). Using biologic mesh with CS was cost-effective when the hernia recurrence using CS alone was 24% or higher (Fig. 3) . The maximum cost of biologic mesh for it to remain cost-effective (ICUR = $50,000/QALY) is $1813.53 (Table 4 ).
DISCUSSION
When describing complex ventral hernias, the literature is unclear in its definition of ''complex.'' Published peer-reviewed articles often use this term to describe ventral hernias that are recurrent, infected, have compromised local tissue (radiated, etc), are large, or involve fistula. 2,12,24,34Y38 Recently, the VHWG classified patients into 4 grades based on the degree of contamination at the surgical site with grade 1 patients having a clean operative field and grade 4 patients having evidence of gross contamination. 3 Patients with established comorbidities that increase the risk of surgical site infection (grade 2) or evidence of wound infection (grades 3 and 4) were defined as having complex ventral hernias and were used in our analysis for CS with and without biologic mesh.
Although CS and biologic mesh repair have both been separately shown to improve outcomes with regard to recurrence for complex ventral hernias, 1,13,15,38Y42 literature exists describing that when used together, a decreased rate of hernia recurrence is obtained but with a higher complication rate. 2, 12, 24 Further complicating the decision process of whether to use biologic mesh with CS is the substantial cost added to the closure by using mesh. Our results (Fig. 2) confirm a higher overall complication rate but lower hernia recurrence rate when using biologic mesh with CS. The strength of cost-utility analysis is its ability to determine the relative importance of health states in determining if an overall intervention is cost-effective. Using biologic mesh is cost-effective using Medicare reimbursement rates ($268.22) as the benefit of decreased recurrence outweighs the negatives of higher associated complications. Using biologic mesh is not cost-effective when using the much higher retail costs ($8095) that hospitals/physicians may pay because the costs outweigh the benefit of decreased recurrence.
Perspective
The cost utility of biologic mesh is dependent on which financial perspective is adopted. We evaluated cost-effectiveness using both a third-party perspective (Medicare) and a hospital/physician perspective (retail costs) and found that the use of biologic mesh was cost-effective when using Medicare reimbursement rates but was cost-ineffective at retail prices. The large difference in the cost of mesh determines the cost-effectiveness of biologic mesh in the treatment of complex ventral hernias, and such a disparity that is highlighted by our results needs to be addressed before the potential adoption of biologic mesh in ventral hernia repair. Policy options that could allow biologic mesh to become cost-effective when also using CS in ventral hernia repair could include the reduction of the mesh's retail price, higher Medicare reimbursement for biologic mesh to the hospital, or a combination of the previously mentioned options.
Sensitivity Analysis
We performed a 1-way sensitivity analysis by varying the complication rate and hernia recurrence rate when repairing complex ventral hernias using CS alone while keeping the complication and recurrence rates constant when using biologic mesh. Our results show that when using Medicare reimbursement rates, it is costeffective to start using biologic mesh when the recurrence rate is 16% or higher when using CS alone. When using retail costs, it is cost-effective to start using biologic mesh when the recurrence rate is 24% or higher when using CS alone (Fig. 3) . Published studies on complex ventral hernia repair using CS alone report an average recurrence rate of 17.3%, which shows that most physicians/hospitals should not use biologic mesh until retail costs are reduced or Medicare reimbursements are increased.
Sensitivity analysis was done to calculate the maximum price of biologic mesh such that it remains cost-effective ($50,000/QALY) and was found to be $1813.53. This price is absolute and does not depend on the size of mesh used. For a 250-cm 2 piece of mesh, this equates to $7.25/cm 2 , less than a quarter of current retail cost FIGURE 3. One-way sensitivity analysis using retail costs for biologic mesh showing the incremental ICUR as the hernia recurrence rate in reconstructions without biologic mesh is varied from 0.24 to 0.78 at 0.01 intervals. Using a maximum willingness to pay of $50,000/QALY, using biologic mesh is cost-effective and should be adopted when the hernia recurrence rate without biologic mesh is 24% or higher.
($32.38/cm 2 ). Having this unique price point will allow hospitals and third-party payers to better negotiate with industry in providing cost-effective health interventions.
The utility of each health state was based on an average of expert opinion and is subject to variability. To test the strength of our decision model, we varied utilities across their standard deviation for each health state (except successful surgery) and this did not change our conclusion, further proving that individual variation in utility estimates did not alter our conclusions.
Limitations
One limitation inherent in cost-effectiveness analysis is its reliance on the literature review. 8,43Y45 Specifically, there is an assumption that the data gathered with regard to the clinical judgment and surgical technique used in performing CS alone or with the addition of biologic mesh have little variability. In reality, the studies used often did not specify specific techniques of CS on a case-bycase basis in their papers so it was not possible to differentiate studies using perforator sparing versus traditional open approaches in CS.
In the same context, several studies used for pooling included retrospective reviews, which also incur the disadvantage of having confounders that can mask the results noted in those studies. Furthermore, until further prospective, randomized, unbiased studies are performed, the decision analysis performed here provides a reasonable cost-utility analysis that can aid in decision making when it comes to using or not using biologic mesh with CS for complex ventral hernia defects. The alternative in not having this cost-utility analysis is a continued status quo reliance on personal experience. Our hope is that the reader uses not only personal experience but also finds the results of this study as an additional aid when considering treatment options in complex ventral hernia cases. Although the results of this study argue against universally using biologic mesh with CS when repairing complex ventral hernias, there maybe instances where biologic mesh can be used. For example, our study assumes that the ventral wall defect can be closed with the advancement techniques of the CS. In situations where a surgeon cannot close the defect in a grossly contaminated field, it may be reasonable to use biologic mesh as a material for closure in addition to the CS. Certainly, the complexities of decision making when attempting fix a complex ventral hernia cannot be answered by any single study. Experience, intraoperative decision making, and fund of knowledge are key aspects in forming an acceptable surgical solution to a very complex problem.
Second, fixation methods using CS and also the placement of mesh vary in the literature. Mesh placement varies depending on which plane the mesh is placed (sublay vs onlay, etc). Most of the patients included in our literature review had underlay mesh placements. Reliance on the literature review assumes fixation styles are similar; this is a limitation to the level 2 cost-effectiveness model. Although this is definitely a limitation, past review papers have grouped CS operations with varying mesh placement while acknowledging this weakness. 2, 20, 27, 29, 38, 46 Third, the patients included in our analysis experienced either recurrent or initial complex ventral hernias. Because recurrent hernias are typically more complex than initial ventral hernias, this may have biased our results. We attempted to control for this patient selection bias by using studies with matched cohorts to analyze complex ventral hernias.
Fourth, patient characteristics entering the study are often varied. Patients often have chronic enterocutaneous fistulas preoperatively, which are traditionally treated with antibiotic control of sepsis, bowel rest, parenteral nutrition, and local wound care before abdominal closure with CS. 17 Patients with fistulas preoperatively were assumed to have undergone this treatment before abdominal closure and any enterocutaneous fistula that occurred postoperatively was treated as a recurrence. 27 Finally, our choice to use biologic mesh with CS to fix complex ventral hernias assumes that permanent mesh is not an option given a contaminated field that would present a high risk of infection with synthetic mesh. 25, 34, 47 Although there have been reports of synthetic, wide-pore mesh being used in some clean-contaminated cases of abdominal wall reconstruction, 34 future unbiased, costutility studies using synthetic mesh with CS to treat ventral hernias are needed which lie outside the scope of this study. Some may argue that the patient group treated with biologic mesh may represent a group with a higher risk for surgical-site infection relative to the group treated with CS alone. This was not the case as both groups had patients with VHWG grade 2 to 4 hernias with most of patients having grade 2 to 3 hernias in both groups (Tables 1 and 2 ). In fact, some authors recommend using CS alone, as opposed to biologic mesh, in contaminated cases. 25 Overall, there is a large amount of ventral hernia literature that describes repair methods using CS with or without biologic mesh. There is a great deal of variation within this literature in not only surgical repair techniques but also reporting parameters such as follow-up periods and treatment plans for hernia repair based on comorbidities and size (in addition to level of contamination). Ideally, one would wish to be able to have all the literature uniform in fixation techniques and patient characteristics to compare ''apples to apples.'' Realistically, this rarely happens, but surgical decisions still need to occur using not only personal experience but also an evidence-based approach. Our study does not show a clear advantage favoring the use of a very expensive technology (biologic mesh) to supplement the advancement CS flap methodology. Although there are f laws inherent in relying on literature review to pool patients, the lack of data clearly favoring biologic mesh should mean that surgeons be cautious of universally using biologic mesh given its expense. Although there may be case-to-case indications for the use of biologic mesh for certain complex ventral hernia repair, our results demonstrate that its routine, universal use with CS does not seem warranted based on the evidence present today.
CONCLUSIONS
The cost utility of biologic mesh with CS in the surgical treatment of complex ventral hernias is dependent on the financial perspective. It is not cost-effective from the perspective of a hospital or surgeon in private practice (retail costs) but is cost-effective from a third-party payer perspective (Medicare reimbursement). The threshold cost of biologic mesh such that it remains cost-effective is $1813.53 (regardless of size), which is significantly lower than current retail costs for practical mesh sizes. The surgeon and hospital should be wary of universally using biologic mesh in complex hernia repair until policy or price negotiations reduce biologic mesh retail costs.
